A nasal spray with the potential to fight Covid-19 and other respiratory viral infections will be tested in the hope of manufacturing it in Australia, and the Federal Government plans to pay for the testing.
The INNA-051 nasal treatment, developed by the Australian biotech company Ena Respiratory, targets the primary site of most respiratory infections, including Covid, and activates immune defence mechanisms in the respiratory tract.
BioNTech, which co-developed a revolutionary mRNA covid-19 vaccine in partnership with Pfizer, hopes to revolutionise another area of pharmaceuticals: vaccine manufacturing. It is developing vaccine factories to sit inside a series of standard metal shipping containers, which it plans to send to parts of the world that lack their own vaccine-manufacturing capabilities-notably Africa.
Each facility, BioNTech says, will be able to produce up to 60m doses of covid vaccines and other vaccines each year, and will cost "significantly less" than conventional factories. If so, this could be the future of drugmaking.
"The safest situation, especially for prolonged contact in crowded
settings, is when everyone is wearing well-fitting N95 respirators."
"Now it’s understood the virus is airborne. Virus-laden particles
build up in the air over time indoors because of breathing and speaking.
"It’s time to rethink and upgrade masks for you and your family."
Here are excellent explainers on why we need to think differently about
masks in response to Omicrom from:> The Conversation > https://bit.ly/3qQy8lr> The ABC > https://ab.co/3nQ8xr4And more about re-use of N95s - https://lnkd.in/ggycyNT7